Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Total Non-Current Liabilities: 2019-2021

Historic Total Non-Current Liabilities for Nurix Therapeutics (NRIX) over the last 1 years, with Aug 2021 value amounting to $117.1 million.

  • Nurix Therapeutics' Total Non-Current Liabilities rose 13.23% to $117.1 million in Q3 2021 from the same period last year, while for Aug 2021 it was $117.1 million, marking a year-over-year increase of 13.23%. This contributed to the annual value of $105.2 million for FY2020, which is 103.02% up from last year.
  • Nurix Therapeutics' Total Non-Current Liabilities amounted to $117.1 million in Q3 2021, which was down 1.60% from $119.0 million recorded in Q2 2021.
  • Over the past 5 years, Nurix Therapeutics' Total Non-Current Liabilities peaked at $125.7 million during Q1 2021, and registered a low of $51.8 million during Q4 2019.
  • For the 3-year period, Nurix Therapeutics' Total Non-Current Liabilities averaged around $103.7 million, with its median value being $111.1 million (2020).
  • Data for Nurix Therapeutics' Total Non-Current Liabilities shows a peak YoY soared of 103.02% (in 2020) over the last 5 years.
  • Over the past 3 years, Nurix Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $51.8 million in 2019, then soared by 103.02% to $105.2 million in 2020, then climbed by 13.23% to $117.1 million in 2021.
  • Its Total Non-Current Liabilities was $117.1 million in Q3 2021, compared to $119.0 million in Q2 2021 and $125.7 million in Q1 2021.